X-linked lymphoproliferative disease (XLP), a rare inherited immunodeficiency involving primarily T-and natural killer (NK) cells is characterised by fulminant infectious mononucleosis, dysgammaglobulinaemia, lymphoproliferative disorders and malignant lymphoma. 1 The gene responsible for XLP has been cloned and named SLAMassociated protein (SAP) or SH2D1A.
2 SAP regulates several critical aspects of immune function, including lymphocyte activation and proliferation, cytotoxicity, cytokine secretion, adhesion and induction of humoral immune responses. XLP patients have inactivating mutations in the SH2 domain of SAP and this results in a significantly increased risk of malignant and non-malignant lymphoproliferative disorders. HSCT is the only curative therapeutic intervention in these patients. 3 We describe the case of a 4-year-old boy who presented (8 months old) with swinging fevers, rash, lymphadenopathy, hepatosplenomegaly and hemophagocytic lymphohistiocytosis secondary to EBV infection. Immunological and genetic testing showed a lack of SAP protein expression and the presence of a previously described point mutation (R55X) in exon 2 of the SH2D1A gene, respectively. A diagnosis of sporadic XLP was confirmed considering there was no family history of the disease. The patient responded rapidly to immunomodulatory treatment together with targeted B-cell directed therapy (rituximab) 4 before undergoing a fully-matched BM SCT from an unrelated donor following reduced intensity conditioning with fludarabine, melphalan and alemtuzumab. Neutrophil engraftment of 0.5 Â 10 9 /L was achieved by day 12 post transplant and had risen to 2.7 Â 10 9 /L by day 19 post transplant. Whole peripheral blood (PB) donor chimerism was quantified using the PowerPlex 16 System (Promega, Madison, WI, USA) and showed 92% donor cells on day 19 post transplant but fell rapidly to 11% by day 76. Repeat analysis for SH2D1A mutation in PB, but not in selected T cells, revealed the presence of mutated sequence only. The discrepancy between the chimerism assay and SH2D1A genetic analyses is likely to be because of differing limits of detection for each method; the chimerism assay has a sensitivity of approximately 3% in detecting minor cell populations, whereas SH2D1A sequencing requires a population of 410% for confirmation of mutation. Taken together, these results raised the potential of graft failure; however, the patient showed no overt signs of graft rejection and had no clinically significant disease. Continuous Myeloablative transplant in XLP patients has generally shown eradication of recipient haematopoietic cells and establishment of full-donor chimerism [5] [6] [7] or stable highlevel (490%) mixed chimerism in whole blood and T-cell lineages. 8 Recent reports of reduced intensity conditioning transplantation in patients with primary immunodeficiency, including some XLP patients, have shown full-donor engraftment up to 16 months post transplant in those XLP patients, 9,10 with a single case reporting mixed chimerism and development of post-transplant EBV reactivation. 11 It has been observed that graft rejection does not occur in some non-malignant disorders once tolerance to donor cells has been established, and that even low levels of donor engraftment in the correct cell lineage may be sufficient for correction of the underlying disease, though this is likely to be disease specific. This is the first reported case of an XLP patient after unrelated myeloablative transplant with sustained low-level chimerism apparent in whole PB and the CD3 þ lineage. The patient continues to remain very well, indicating that it is possible for a very low level of donor cells to engraft, stabilise and correct the underlying disease in this severe form of X-linked immune deficiency syndrome.
